A new genomic urine test can predict bladder cancer as many as 12 years before clinical signs and symptoms emerge, according to a study presented at the annual meeting of the American Urological Association, held from April 28 to May 1 in Chicago.
Yair Lotan, M.D., from the UT Southwestern Medical Center in Dallas, and colleagues examined the effectiveness of screening for preclinical urinary carcinoma (UC) with a modified UroAmp (Convergent Genomics) genomic profiling test using 10 genes. The analysis included a model evaluation case-control design with 96 controls and 70 UC cases, as well as a nested case-control design within the Golestan Cohort Study (50,045 participants followed for up to 12 years).
The researchers found that the UC screening model was trained to a sensitiv...
Read More
Recent Comments